[ Price : $8.95]
Bausch + Lomb recalls its enVista intraocular lenses after the company received reports of complications, which it says could not ...[ Price : $8.95]
Six Sidley attorneys raise several practical questions arising from a Texas federal court decision finding that FDA does not have ...[ Price : $8.95]
FDA regulatory experts warn that the agencys user fee programs could be in jeopardy based on sweeping layoffs and political indiff...[ Price : $8.95]
Physician Douglas Smith petitions FDA to take 11 steps to curtail the use of the indications of opioid addiction and opioid use di...[ Price : $8.95]
Rhythm Pharmaceuticals announces positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for tr...[ Price : $8.95]
FDA accepts for review a Teva Pharmaceuticals supplemental BLA for Ajovy (fremanezumab-vfrm) to expand the indication to include p...[ Price : $8.95]
Former CDRH director Jeff Shuren says recent staff cuts at CDRH will likely lead to longer review times.[ Price : $8.95]
FDA grants Allogene Therapeutics three fast track designations for ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic...